NCT06607185 2026-04-22A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsEli Lilly and CompanyPhase 1 Active not recruiting750 enrolled
NCT04920032 2026-04-13Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon AdenocarcinomasUniversity of California, IrvinePhase 1 Recruiting22 enrolled